Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 313
interventional 269
Observational 41
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Biological 189
Drug 44
Biological|placebo 12
Drug|placebo 6
Other 4
Procedure 3
Biological|Drug 2
Biological|Other 2
Device 2
Biological|Dietary Supplement 1
Biological|Procedure 1
Combination Product 1
Dietary Supplement 1
Drug|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 58
United Kingdom 25
United States|Puerto Rico 14
Finland 7
China 6
Germany 6
Italy 6
Korea, Republic of 6
United States|Canada 6
Vietnam 6
Japan 4
NA 4
Philippines 4
Australia 3
Austria|Germany 3
Canada 3
Chile|Colombia|Panama 3
Finland|Poland 3
France 3
India 3
Indonesia 3
Lebanon 3
Uganda 3
Belgium 2
Canada|United Kingdom 2
Chile 2
Denmark 2
France|Germany 2
Malawi 2
Saudi Arabia 2
South Africa 2
United States|Poland 2
Angola 1
Argentina 1
Argentina|Chile|Czech Republic|Hungary|Italy 1
Argentina|Colombia 1
Argentina|Mexico 1
Australia|Canada 1
Australia|Canada|Chile 1
Australia|Canada|Czechia|Panama|South Africa|Turkey 1
Austria|Czech Republic|Finland|Germany|Italy 1
Austria|Germany|Greece 1
Austria|Greece 1
Bangladesh 1
Belgium|Czech Republic|Germany|Italy|Spain|United Kingdom 1
Botswana 1
Brazil|Estonia|Finland|France|Mexico|Russian Federation|South Africa|Spain|Turkey 1
Brazil|Hungary|Peru|Spain 1
Canada|United States 1
Congo, The Democratic Republic of the 1
Costa Rica 1
Czech Republic|Finland 1
Czech Republic|Germany 1
Czech Republic|Italy|Spain|United Kingdom 1
Czechia 1
Czechia|Finland|Italy|Romania|Spain 1
Denmark|Finland|Germany 1
Denmark|Sweden 1
Dominican Republic|Estonia|Thailand 1
Dominican Republic|Germany|Korea, Republic of 1
Finland|Germany|Hungary|Spain 1
Germany|Belgium|Czechia|Italy|Spain|United Kingdom 1
Germany|Poland 1
India|Lebanon|Philippines|Saudi Arabia 1
India|Philippines 1
India|Philippines|Taiwan 1
India|Russian Federation 1
Indonesia|Vietnam 1
Israel 1
Italy|Australia|Belgium|Canada|Germany 1
Italy|Poland|Russian Federation|Spain|United Kingdom 1
Korea, Republic of|Mexico|Russian Federation|Thailand 1
Lebanon|Mexico 1
Lebanon|Philippines 1
Mexico 1
Mexico|Taiwan 1
Netherlands 1
Niger 1
Norway|Uganda 1
Panama|Philippines|Thailand 1
Philippines|Saudi Arabia 1
Poland 1
Poland|Spain 1
Russian Federation 1
South Africa|Uganda 1
Spain 1
Spain|Estonia|Germany 1
Taiwan 1
United States|Argentina|Colombia 1
United States|Australia|Canada 1
United States|Chile 1
United States|China|Costa Rica|Guatemala|Panama|Peru 1
United States|Czechia 1
United States|Czechia|Denmark|Finland|Germany|Sweden 1
United States|Finland|Poland 1
United States|India|Kenya|Peru|South Africa|Thailand|Uganda|Zimbabwe 1
United States|Italy 1
United States|Peru 1
United States|Thailand 1
United States|Ukraine 1
Zimbabwe 1

Sites per Study

Site_count Study_Count
1 71
2 20
3 25
4 10
5 6
6 7
7 10
8 13
9 4
10 6
11 6
12 3
13 4
14 8
15 5
16 2
17 2
19 5
20 3
22 1
23 1
24 1
25 2
26 2
28 3
29 2
30 3
31 1
32 5
33 1
34 1
36 3
37 3
38 1
39 2
40 2
42 1
45 1
46 1
49 2
50 1
51 1
54 1
56 2
58 1
59 1
60 1
63 1
68 1
69 1
72 2
80 1
88 1
89 2
90 1
130 1
153 1

Phase

Phase Study_Count
Phase 3 105
Phase 2 76
Phase 4 39
N/A 21
Phase 1 11
Phase 1/Phase 2 9
Phase 2/Phase 3 7
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 27
2 80
3 51
4 33
5 12
6 13
7 4
8 4
9 3
11 1
12 2
13 1
14 1
17 1
NA 36

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 35 5.00 18.0 12.0000 9.0000 60.0000 13.0000 20.000
1st Qu. 35 39.75 34.5 22.0000 128.7500 129.0000 300.0000 131.000
Median 35 92.00 55.0 51.0000 286.0000 817.0000 560.0000 324.000
Mean 35 1321.60 193.7 120.3333 420.2368 856.2857 908.6667 1433.949
3rd Qu. 35 607.00 95.0 176.0000 524.2500 1609.5000 1072.0000 602.000
Max. 35 7040.00 1177.0 384.0000 1885.0000 1640.0000 7744.0000 34489.000

Trial Group Type

group_type Group_Count
Experimental 539
Active Comparator 184
NA 36
Other 28
Placebo Comparator 17
No Intervention 8

Intervention Model

intervention_model Study_Count
Parallel Assignment 207
Single Group Assignment 37
NA 19
Crossover Assignment 2
Factorial Assignment 2
Sequential Assignment 2

Primary Purpose

primary_purpose Study_Count
Prevention 206
Treatment 53
Other 3
Basic Science 2
Health Services Research 2
Diagnostic 1
Screening 1
Supportive Care 1

Observational Studies

Studies by Country

Country Study_Count
United States 9
France 6
NA 4
China 2
Australia 1
Belgium 1
Brazil 1
Burkina Faso|Ghana|Kenya 1
Canada 1
Denmark 1
Germany|Italy|United Kingdom 1
Korea, Republic of 1
Philippines 1
Russian Federation 1
Spain 1
Suriname 1
Sweden 1
Switzerland 1
Thailand 1
Turkey 1
Uganda 1
United Kingdom 1
United States|Canada|Israel|Singapore|United Kingdom 1
Zimbabwe 1

Sites per Study

Site_count Study_Count
1 26
2 2
3 3
4 1
5 2
7 1
12 1
18 1
20 1
22 1
39 1
52 1

Enrollment Metrics

Measure Observational
Min 1.000
1st Qu 101.000
Median 340.000
Mean 4357.098
3rd Qu 1000.000
Max 62626.000

Observation Model

observational_model Study_Count
Cohort 26
Other 4
NA 4
Case Control 3
Case-Only 2
Case-Control 1
Defined Population, Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 24
Retrospective 9
Other 3
Cross-Sectional 2
NA 2
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
China 2
United States 1

Sites per Study

Site_count Study_Count
1 1
2 2

Enrollment Metrics

Measure Registries
Min 93.0
1st Qu 296.5
Median 500.0
Mean 3531.0
3rd Qu 5250.0
Max 10000.0

Registry Model

observational_model Study_Count
Cohort 3

Time Perspective

time_perspective Study_Count
Prospective 2
Other 1

Follow-up

target_duration Study_Count
2 Years 2
10 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03205371 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers https://ClinicalTrials.gov/show/NCT03205371 Completed Sanofi 2018-07-19
NCT03205358 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers https://ClinicalTrials.gov/show/NCT03205358 Completed Sanofi 2015-08-19
NCT03125616 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B https://ClinicalTrials.gov/show/NCT03125616 Active, not recruiting St George’s, University of London 2019-09-02
NCT03112031 Treatment With Tamoxifen in Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT03112031 Completed Oxford University Clinical Research Unit, Vietnam 2018-07-17
NCT03100786 Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis https://ClinicalTrials.gov/show/NCT03100786 Recruiting Oxford University Clinical Research Unit, Vietnam 2021-12-01
NCT03092817 Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) https://ClinicalTrials.gov/show/NCT03092817 Recruiting Oxford University Clinical Research Unit, Vietnam 2021-04-01
NCT03077438 Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years https://ClinicalTrials.gov/show/NCT03077438 Completed Sanofi 2017-10-10
NCT02986854 Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination https://ClinicalTrials.gov/show/NCT02986854 Completed GlaxoSmithKline 2017-07-17
NCT02955862 Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report https://ClinicalTrials.gov/show/NCT02955862 Completed National Hospital for Tropical Diseases, Hanoi, Vietnam 2017-09-30
NCT02955797 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers https://ClinicalTrials.gov/show/NCT02955797 Completed Sanofi 2017-10-26
NCT02946385 Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents https://ClinicalTrials.gov/show/NCT02946385 Completed GlaxoSmithKline 2018-02-13
NCT02881957 Hypovitaminosis D in Neurocritical Patients https://ClinicalTrials.gov/show/NCT02881957 Completed University of Utah 2018-10-10
NCT02864927 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea https://ClinicalTrials.gov/show/NCT02864927 Completed Sanofi 2019-06-12
NCT02842866 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older https://ClinicalTrials.gov/show/NCT02842866 Completed Sanofi 2017-02-13
NCT02842853 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine https://ClinicalTrials.gov/show/NCT02842853 Completed Sanofi 2017-02-28
NCT02752906 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine https://ClinicalTrials.gov/show/NCT02752906 Completed Sanofi 2016-12-19
NCT02724046 Ciprofloxacin for the Prevention of Meningococcal Meningitis https://ClinicalTrials.gov/show/NCT02724046 Completed Epicentre 2017-05-30
NCT02640404 Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam https://ClinicalTrials.gov/show/NCT02640404 Completed Sanofi 2016-12-05
NCT02639351 Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine https://ClinicalTrials.gov/show/NCT02639351 Completed GlaxoSmithKline 2017-08-31
NCT02633787 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier https://ClinicalTrials.gov/show/NCT02633787 Completed Sanofi 2016-02-29
NCT02591290 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT02591290 Completed Sanofi 2016-03-16
NCT03621670 GlaxoSmithKline’s (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants https://ClinicalTrials.gov/show/NCT03621670 Recruiting GlaxoSmithKline 2023-10-09
NCT02531698 A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years https://ClinicalTrials.gov/show/NCT02531698 Completed Pfizer 2017-03-31
NCT02526394 Pertussis and Meningitis C Concomitant Vaccination in Adolescents https://ClinicalTrials.gov/show/NCT02526394 Completed Public Health England 2017-03-31
NCT02451514 A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) https://ClinicalTrials.gov/show/NCT02451514 Completed GlaxoSmithKline 2015-11-30
NCT02446743 Combined Study - Phase 3b MenB Long Term Persistence in Adolescents https://ClinicalTrials.gov/show/NCT02446743 Completed GlaxoSmithKline 2016-09-23
NCT02446691 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations https://ClinicalTrials.gov/show/NCT02446691 Completed GlaxoSmithKline 2017-12-28
NCT02398396 Investigating Meningococcal Vaccines in Adults https://ClinicalTrials.gov/show/NCT02398396 Active, not recruiting University of Oxford 2015-11-30
NCT02285777 Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents https://ClinicalTrials.gov/show/NCT02285777 Completed GlaxoSmithKline 2015-03-26
NCT02274285 DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants https://ClinicalTrials.gov/show/NCT02274285 Completed Sanofi 2016-05-28
NCT02237365 A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis https://ClinicalTrials.gov/show/NCT02237365 Completed Oxford University Clinical Research Unit, Vietnam 2016-06-24
NCT02212457 Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents https://ClinicalTrials.gov/show/NCT02212457 Completed GlaxoSmithKline 2015-05-22
NCT02199691 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents https://ClinicalTrials.gov/show/NCT02199691 Completed Sanofi 2015-10-02
NCT02173704 Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. https://ClinicalTrials.gov/show/NCT02173704 Completed GlaxoSmithKline 2015-12-25
NCT02169882 High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study https://ClinicalTrials.gov/show/NCT02169882 Completed Universitas Padjadjaran 2016-11-05
NCT02141516 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. https://ClinicalTrials.gov/show/NCT02141516 Completed Novartis 2015-03-31
NCT02140762 Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents https://ClinicalTrials.gov/show/NCT02140762 Completed Novartis 2014-11-30
NCT02106390 Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants https://ClinicalTrials.gov/show/NCT02106390 Completed GlaxoSmithKline 2016-10-14
NCT01274897 A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea https://ClinicalTrials.gov/show/NCT01274897 Completed Novartis 2011-03-31
NCT01272180 Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults https://ClinicalTrials.gov/show/NCT01272180 Completed Novartis 2011-10-31
NCT01270503 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines https://ClinicalTrials.gov/show/NCT01270503 Completed Sanofi 2013-12-31
NCT01994629 Safety and Immunogenicity of One Dose of Novartis’ Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals’ Meningococcal ACWY-TT Vaccine in Healthy Toddlers https://ClinicalTrials.gov/show/NCT01994629 Completed Novartis 2014-04-30
NCT01992536 Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) https://ClinicalTrials.gov/show/NCT01992536 Completed Novartis 2014-05-31
NCT01984125 Testing the Use of Prompts to Increase Adolescent Immunization Rates https://ClinicalTrials.gov/show/NCT01984125 Completed University of California, Los Angeles 2013-01-31
NCT01973218 Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. https://ClinicalTrials.gov/show/NCT01973218 Completed Novartis 2014-04-30
NCT01939158 Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer’s Prevenar 13â„¢Vaccine https://ClinicalTrials.gov/show/NCT01939158 Completed Pfizer 2019-12-05
NCT01934140 Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals’ MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination https://ClinicalTrials.gov/show/NCT01934140 Completed Pfizer 2018-02-28
NCT01911221 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. https://ClinicalTrials.gov/show/NCT01911221 Completed Novartis 2014-04-30
NCT01904448 Auditory Brainstem Implantation in Young Children https://ClinicalTrials.gov/show/NCT01904448 Completed University of North Carolina, Chapel Hill 2017-10-01
NCT01900899 Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children https://ClinicalTrials.gov/show/NCT01900899 Completed Pfizer 2017-11-30
NCT01897402 Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine https://ClinicalTrials.gov/show/NCT01897402 Completed JN-International Medical Corporation 2014-05-31
NCT01896596 Hepatitis B Vaccination in Infants https://ClinicalTrials.gov/show/NCT01896596 Completed Public Health England 2017-04-30
NCT01890759 Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation https://ClinicalTrials.gov/show/NCT01890759 Completed Sanofi 2016-04-12
NCT01823536 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose https://ClinicalTrials.gov/show/NCT01823536 Completed Novartis 2013-10-31
NCT01802502 Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation https://ClinicalTrials.gov/show/NCT01802502 Completed Universitas Padjadjaran 2013-10-31
NCT01802385 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT01802385 Completed University of Minnesota 2017-09-30
NCT01782066 Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines https://ClinicalTrials.gov/show/NCT01782066 Completed Leiden University Medical Center 2014-02-28
NCT01777308 Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination https://ClinicalTrials.gov/show/NCT01777308 Completed GlaxoSmithKline 2014-07-03
NCT01767376 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age https://ClinicalTrials.gov/show/NCT01767376 Completed GlaxoSmithKline 2014-01-16
NCT01766206 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea https://ClinicalTrials.gov/show/NCT01766206 Completed GlaxoSmithKline 2018-01-22
NCT01755689 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults https://ClinicalTrials.gov/show/NCT01755689 Completed GlaxoSmithKline 2014-04-29
NCT01745679 Pharmacological Study of High Doses of Ceftriaxone in Meningitidis https://ClinicalTrials.gov/show/NCT01745679 Completed Nantes University Hospital 2015-12-31
NCT01732627 Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older https://ClinicalTrials.gov/show/NCT01732627 Completed Sanofi 2013-01-17
NCT01725217 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia https://ClinicalTrials.gov/show/NCT01725217 Completed Novartis 2013-03-31
NCT01717638 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 https://ClinicalTrials.gov/show/NCT01717638 Completed Novartis 2013-09-30
NCT01682876 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. https://ClinicalTrials.gov/show/NCT01682876 Completed GlaxoSmithKline 2013-07-02
NCT01659996 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age https://ClinicalTrials.gov/show/NCT01659996 Completed Sanofi 2014-11-30
NCT01642589 Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea https://ClinicalTrials.gov/show/NCT01642589 Completed Sanofi 2013-01-31
NCT01641042 Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects https://ClinicalTrials.gov/show/NCT01641042 Completed GlaxoSmithKline 2014-10-10
NCT01593514 Understanding the Immune Response to Two Different Meningitis Vaccines https://ClinicalTrials.gov/show/NCT01593514 Completed University of Oxford 2013-04-30
NCT01589289 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC https://ClinicalTrials.gov/show/NCT01589289 Completed Institute of Tropical Medicine, Belgium 2015-01-31
NCT01580033 Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine https://ClinicalTrials.gov/show/NCT01580033 Completed Jiangsu Province Centers for Disease Control and Prevention 2012-09-30
NCT01554124 Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis https://ClinicalTrials.gov/show/NCT01554124 Completed PENTA Foundation 2014-12-31
NCT01547715 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India https://ClinicalTrials.gov/show/NCT01547715 Completed Novartis 2014-04-30
NCT01543087 Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose https://ClinicalTrials.gov/show/NCT01543087 Completed Pfizer 2018-01-05
NCT01540838 Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis https://ClinicalTrials.gov/show/NCT01540838 Completed University of Helsinki 2017-02-28
NCT01535469 Operational Research for Cryptococcal Antigen Screening https://ClinicalTrials.gov/show/NCT01535469 Completed University of Minnesota 2015-06-30
NCT01519713 Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects https://ClinicalTrials.gov/show/NCT01519713 Completed Sanofi 2012-09-30
NCT03927313 Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM https://ClinicalTrials.gov/show/NCT03927313 Recruiting University of Cape Town 2020-06-30
NCT01482052 Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis https://ClinicalTrials.gov/show/NCT01482052 Completed JN-International Medical Corporation 2013-01-31
NCT01478347 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults https://ClinicalTrials.gov/show/NCT01478347 Completed Novartis 2014-03-31
NCT01466387 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults https://ClinicalTrials.gov/show/NCT01466387 Completed Novartis 2012-04-30
NCT01453348 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine https://ClinicalTrials.gov/show/NCT01453348 Completed Novartis 2012-01-31
NCT01442675 Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine https://ClinicalTrials.gov/show/NCT01442675 Completed Sanofi 2012-06-30
NCT01434680 Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers https://ClinicalTrials.gov/show/NCT01434680 Completed Novartis 2012-11-30
NCT01430611 Study of Sanofi Pasteur and Lanzhou Institute’s Meningococcal (Group A and C) Polysaccharide Vaccine in Children https://ClinicalTrials.gov/show/NCT01430611 Completed Sanofi 2012-08-31
NCT01428908 Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children https://ClinicalTrials.gov/show/NCT01428908 Completed Jiangsu Province Centers for Disease Control and Prevention 2011-12-31
NCT01424644 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents https://ClinicalTrials.gov/show/NCT01424644 Completed Novartis 2012-12-31
NCT01423084 Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years https://ClinicalTrials.gov/show/NCT01423084 Completed Novartis 2011-12-31
NCT01410474 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan https://ClinicalTrials.gov/show/NCT01410474 Completed Novartis 2012-01-31
NCT01373710 Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis https://ClinicalTrials.gov/show/NCT01373710 Completed Institut Curie 2018-04-30
NCT01367158 Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines https://ClinicalTrials.gov/show/NCT01367158 Completed Novartis 2012-01-31
NCT01359449 Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations https://ClinicalTrials.gov/show/NCT01359449 Completed Sanofi 2012-07-31
NCT01345721 Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine https://ClinicalTrials.gov/show/NCT01345721 Completed Novartis 2011-09-30
NCT01340898 Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers https://ClinicalTrials.gov/show/NCT01340898 Completed GlaxoSmithKline 2014-08-04
NCT01339923 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years https://ClinicalTrials.gov/show/NCT01339923 Completed Novartis 2014-01-31
NCT04368429 Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age https://ClinicalTrials.gov/show/NCT04368429 Recruiting Sanofi 2020-12-31
NCT04358731 Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age https://ClinicalTrials.gov/show/NCT04358731 Recruiting Serum Institute of India Pvt. Ltd. 2020-06-10
NCT04236960 Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population. https://ClinicalTrials.gov/show/NCT04236960 Completed Walvax Biotechnology Co., Ltd. 2019-09-16
NCT04142242 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 https://ClinicalTrials.gov/show/NCT04142242 Recruiting Sanofi 2020-02-14
NCT04135053 A Controlled Study to Assess Safety, Colonisation and Immunogenicity of Reconstituted Lyophilised Neisseria Lactamica https://ClinicalTrials.gov/show/NCT04135053 Recruiting University of Southampton 2020-02-01
NCT04084769 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4) https://ClinicalTrials.gov/show/NCT04084769 Active, not recruiting Sanofi 2020-10-31
NCT04080921 Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis https://ClinicalTrials.gov/show/NCT04080921 Completed Vinmec Research Institute of Stem Cell and Gene Technology 2019-06-30
NCT04031833 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) https://ClinicalTrials.gov/show/NCT04031833 Recruiting Matinas BioPharma Nanotechnologies, Inc. 2021-04-30
NCT03890367 Study of a Quadrivalent Meningococcal Conjugate Vaccine Compared With Two Meningococcal Reference Vaccines in Europeans Toddlers https://ClinicalTrials.gov/show/NCT03890367 Recruiting Sanofi 2020-10-31
NCT03787940 Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis https://ClinicalTrials.gov/show/NCT03787940 Recruiting Beijing Chest Hospital 2021-12-31
NCT03694405 Adolescent MenACWY Booster Study https://ClinicalTrials.gov/show/NCT03694405 Recruiting Canadian Immunization Research Network 2020-12-31
NCT03682939 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population https://ClinicalTrials.gov/show/NCT03682939 Recruiting St George’s, University of London 2020-06-30
NCT03673462 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers https://ClinicalTrials.gov/show/NCT03673462 Recruiting Sanofi 2023-03-31
NCT03652610 A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals’ Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age https://ClinicalTrials.gov/show/NCT03652610 Completed GlaxoSmithKline 2019-01-17
NCT03632720 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom https://ClinicalTrials.gov/show/NCT03632720 Recruiting Sanofi 2022-06-30
NCT03630705 Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico https://ClinicalTrials.gov/show/NCT03630705 Recruiting Sanofi 2022-12-31
NCT03630250 Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA) https://ClinicalTrials.gov/show/NCT03630250 Completed University of Southampton 2019-09-01
NCT03587207 Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals’ MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years https://ClinicalTrials.gov/show/NCT03587207 Completed GlaxoSmithKline 2018-12-19
NCT03547271 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe https://ClinicalTrials.gov/show/NCT03547271 Recruiting Sanofi 2023-08-31
NCT03537508 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US https://ClinicalTrials.gov/show/NCT03537508 Recruiting Sanofi 2022-12-31
NCT03480191 Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis https://ClinicalTrials.gov/show/NCT03480191 Recruiting Centre Hospitalier Universitaire Dijon 2021-06-30
NCT03476135 Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children https://ClinicalTrials.gov/show/NCT03476135 Completed Sanofi 2018-09-10
NCT03421002 Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis https://ClinicalTrials.gov/show/NCT03421002 Completed Astellas Pharma Inc 2018-04-10
NCT01266993 Persistence and Booster Study of GSK Biologicals’ Meningococcal Vaccine (GSK134612) in Healthy Children https://ClinicalTrials.gov/show/NCT01266993 Completed GlaxoSmithKline 2014-03-31
NCT01247909 Infant Severe Sepsis and Bacterial Meningitis in Malawi https://ClinicalTrials.gov/show/NCT01247909 Completed University of Malawi College of Medicine 2015-02-28
NCT01239043 Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination https://ClinicalTrials.gov/show/NCT01239043 Completed Sanofi 2011-04-30
NCT01235975 Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years https://ClinicalTrials.gov/show/NCT01235975 Completed GlaxoSmithKline 2011-07-29
NCT01214837 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life https://ClinicalTrials.gov/show/NCT01214837 Completed Novartis 2012-04-30
NCT01210885 Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents https://ClinicalTrials.gov/show/NCT01210885 Completed Novartis 2011-07-31
NCT01192997 Comparison of Two Meningococcal ACWY Conjugate Vaccines https://ClinicalTrials.gov/show/NCT01192997 Completed Public Health England 2013-10-31
NCT01165242 Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults https://ClinicalTrials.gov/show/NCT01165242 Completed GlaxoSmithKline 2011-02-25
NCT01158755 Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study https://ClinicalTrials.gov/show/NCT01158755 Completed Universitas Padjadjaran 2011-12-31
NCT01154088 Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevaxâ„¢ ACWY in Healthy 18-25 Year Olds https://ClinicalTrials.gov/show/NCT01154088 Completed GlaxoSmithKline 2010-12-30
NCT01148524 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 https://ClinicalTrials.gov/show/NCT01148524 Completed Novartis 2012-01-31
NCT01148017 Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine https://ClinicalTrials.gov/show/NCT01148017 Completed Novartis 2013-04-30
NCT01144663 Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines https://ClinicalTrials.gov/show/NCT01144663 Completed GlaxoSmithKline 2012-06-22
NCT01139021 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age https://ClinicalTrials.gov/show/NCT01139021 Completed Novartis 2010-11-30
NCT01129518 Can we Reduce the Number of Vaccine Injections for Children? https://ClinicalTrials.gov/show/NCT01129518 Completed University of Oxford 2013-07-31
NCT01086969 A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India https://ClinicalTrials.gov/show/NCT01086969 Completed Sanofi 2011-02-28
NCT01075152 Cryptococcal Optimal ART Timing Trial https://ClinicalTrials.gov/show/NCT01075152 Completed University of Minnesota 2012-10-31
NCT01049035 A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers https://ClinicalTrials.gov/show/NCT01049035 Completed Sanofi 2012-02-13
NCT01027351 Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine https://ClinicalTrials.gov/show/NCT01027351 Completed Novartis 2010-09-30
NCT01026974 Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine https://ClinicalTrials.gov/show/NCT01026974 Completed Novartis 2010-09-30
NCT01018732 A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY https://ClinicalTrials.gov/show/NCT01018732 Completed Novartis 2010-07-31
NCT01000311 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months https://ClinicalTrials.gov/show/NCT01000311 Completed Novartis 2011-11-30
NCT00976040 Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00976040 Completed Botswana-UPenn Partnership 2011-11-30
NCT00974363 Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 https://ClinicalTrials.gov/show/NCT00974363 Completed GlaxoSmithKline 2013-05-31
NCT00962624 Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults https://ClinicalTrials.gov/show/NCT00962624 Completed Public Health England 2011-03-31
NCT00955682 Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 https://ClinicalTrials.gov/show/NCT00955682 Completed GlaxoSmithKline 2009-12-16
NCT00944034 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 https://ClinicalTrials.gov/show/NCT00944034 Completed Novartis 2011-08-31
NCT00937521 Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants https://ClinicalTrials.gov/show/NCT00937521 Completed Novartis 2010-11-30
NCT00924820 A Pilot Study of Bevacizumab for Neoplastic Meningitis https://ClinicalTrials.gov/show/NCT00924820 Completed M.D. Anderson Cancer Center 2015-09-30
NCT00901940 Understanding the Immune Response to Meningitis Vaccines https://ClinicalTrials.gov/show/NCT00901940 Completed University of Oxford 2010-10-31
NCT00885703 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals https://ClinicalTrials.gov/show/NCT00885703 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2017-01-12
NCT00874549 Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years https://ClinicalTrials.gov/show/NCT00874549 Completed Sanofi 2008-01-31
NCT00856297 Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine https://ClinicalTrials.gov/show/NCT00856297 Completed Novartis 2012-11-30
NCT00854867 Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis. https://ClinicalTrials.gov/show/NCT00854867 Completed Mundipharma Research Limited 2012-10-31
NCT00850603 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® https://ClinicalTrials.gov/show/NCT00850603 Completed Sanofi 2003-05-31
NCT00847145 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers https://ClinicalTrials.gov/show/NCT00847145 Completed Novartis 2010-08-31
NCT00830856 Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa https://ClinicalTrials.gov/show/NCT00830856 Completed University of Zimbabwe 2008-10-31
NCT00806195 Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants https://ClinicalTrials.gov/show/NCT00806195 Completed Novartis 2011-03-31
NCT03089086 South Australian Meningococcal B Vaccine Herd Immunity Study https://ClinicalTrials.gov/show/NCT03089086 Completed University of Adelaide 2018-07-13
NCT03433482 A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals’ Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age https://ClinicalTrials.gov/show/NCT03433482 Completed GlaxoSmithKline 2019-07-26
NCT01962207 The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination https://ClinicalTrials.gov/show/NCT01962207 Completed Pfizer 2017-12-31
NCT03691610 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers https://ClinicalTrials.gov/show/NCT03691610 Recruiting Sanofi 2024-05-31
NCT00777790 Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents https://ClinicalTrials.gov/show/NCT00777790 Completed Sanofi 2004-04-30
NCT00777257 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine https://ClinicalTrials.gov/show/NCT00777257 Completed Sanofi 2007-03-31
NCT00774384 Regulation of Mucosal Immune Response to Systemic MenB Vaccine https://ClinicalTrials.gov/show/NCT00774384 Completed University Hospitals Bristol NHS Foundation Trust 2011-11-30
NCT00772070 Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine https://ClinicalTrials.gov/show/NCT00772070 Completed Sanofi 2003-08-31
NCT00771849 Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children https://ClinicalTrials.gov/show/NCT00771849 Completed Sanofi 2004-03-31
NCT00758264 Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration https://ClinicalTrials.gov/show/NCT00758264 Completed GlaxoSmithKline 2009-06-02
NCT00721396 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules https://ClinicalTrials.gov/show/NCT00721396 Completed Novartis 2010-07-31
NCT00718666 The Long-term Antibody Persistence of GSK Biologicals’ Meningococcal Vaccine GSK134612 in Healthy Toddlers https://ClinicalTrials.gov/show/NCT00718666 Completed GlaxoSmithKline 2013-11-13
NCT00715910 The Long-term Antibody Persistence of GSK Biologicals’ Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults https://ClinicalTrials.gov/show/NCT00715910 Completed GlaxoSmithKline 2013-04-30
NCT00715234 Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients https://ClinicalTrials.gov/show/NCT00715234 Completed University of Colorado, Denver 2009-12-31
NCT00707785 Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis https://ClinicalTrials.gov/show/NCT00707785 Completed Johns Hopkins University 2011-04-30
NCT00700713 Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26 https://ClinicalTrials.gov/show/NCT00700713 Completed Sanofi 2009-02-28
NCT00700635 Dose Comparison Study of Menactra® in US Children https://ClinicalTrials.gov/show/NCT00700635 Completed Sanofi 2009-05-31
NCT00678652 Phase 1 Safety and Immunogenicity of Meningococcal Vaccine https://ClinicalTrials.gov/show/NCT00678652 Completed U.S. Army Medical Research and Development Command 2009-08-31
NCT00674674 Phase 1 Intrathecal Topotecan for Neoplastic Meningitis https://ClinicalTrials.gov/show/NCT00674674 Completed Baylor College of Medicine 2010-08-31
NCT00674583 Comparison of GSK Biologicals’ Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children https://ClinicalTrials.gov/show/NCT00674583 Completed GlaxoSmithKline 2008-09-02
NCT00667602 Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers https://ClinicalTrials.gov/show/NCT00667602 Completed Novartis 2009-07-31
NCT00661713 Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules https://ClinicalTrials.gov/show/NCT00661713 Completed Novartis 2010-04-30
NCT00661557 Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects https://ClinicalTrials.gov/show/NCT00661557 Completed GlaxoSmithKline 2008-12-19
NCT00643916 Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age https://ClinicalTrials.gov/show/NCT00643916 Completed Sanofi 2006-03-31
NCT00631995 Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers https://ClinicalTrials.gov/show/NCT00631995 Completed Sanofi 2009-02-28
NCT00626327 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers https://ClinicalTrials.gov/show/NCT00626327 Completed Novartis 2010-07-31
NCT00625677 Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life https://ClinicalTrials.gov/show/NCT00625677 Completed Public Health England 2010-03-31
NCT00619203 Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis https://ClinicalTrials.gov/show/NCT00619203 Completed University of Malawi College of Medicine 2012-03-31
NCT00616421 Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children https://ClinicalTrials.gov/show/NCT00616421 Completed Novartis 2009-04-30
NCT00614614 Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 https://ClinicalTrials.gov/show/NCT00614614 Completed GlaxoSmithKline 2009-07-31
NCT00601731 Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months https://ClinicalTrials.gov/show/NCT00601731 Completed Novartis 2010-07-31
NCT00560313 Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults https://ClinicalTrials.gov/show/NCT00560313 Completed Novartis 2009-11-30
NCT00539032 Immunology and Safety of Menactra® in Children in Saudi Arabia https://ClinicalTrials.gov/show/NCT00539032 Completed Sanofi 2008-08-31
NCT00518180 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents https://ClinicalTrials.gov/show/NCT00518180 Completed Novartis 2008-04-30
NCT00514904 Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevaxâ„¢ in 2-10 Year Old Subjects https://ClinicalTrials.gov/show/NCT00514904 Completed GlaxoSmithKline 2008-09-03
NCT00508261 Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexaâ„¢ Versus Individual Administration of Each Vaccine https://ClinicalTrials.gov/show/NCT00508261 Completed GlaxoSmithKline 2008-05-26
NCT00488683 B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants https://ClinicalTrials.gov/show/NCT00488683 Completed Novartis 2009-05-31
NCT00483574 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers https://ClinicalTrials.gov/show/NCT00483574 Completed Sanofi 2009-01-31
NCT00474526 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants https://ClinicalTrials.gov/show/NCT00474526 Completed Novartis 2008-09-30
NCT00474487 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults https://ClinicalTrials.gov/show/NCT00474487 Completed Novartis 2007-08-31
NCT00474266 Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetraâ„¢ to 12-23 Month-Old Children https://ClinicalTrials.gov/show/NCT00474266 Completed GlaxoSmithKline 2008-02-26
NCT00471081 Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. https://ClinicalTrials.gov/show/NCT00471081 Completed GlaxoSmithKline 2008-10-23
NCT00465816 Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals’ Meningococcal Vaccine 134612 https://ClinicalTrials.gov/show/NCT00465816 Completed GlaxoSmithKline 2008-04-28
NCT00464815 Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevaxâ„¢ in 11-17 Year-Old Subjects https://ClinicalTrials.gov/show/NCT00464815 Completed GlaxoSmithKline 2008-04-16
NCT00459316 Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth https://ClinicalTrials.gov/show/NCT00459316 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2013-03-31
NCT00454909 Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. https://ClinicalTrials.gov/show/NCT00454909 Completed GlaxoSmithKline 2007-10-31
NCT00453986 Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarixâ„¢ to 18-55 Year-Old Adults https://ClinicalTrials.gov/show/NCT00453986 Completed GlaxoSmithKline 2007-11-30
NCT00450437 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults https://ClinicalTrials.gov/show/NCT00450437 Completed Novartis 2007-08-31
NCT00444951 Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia https://ClinicalTrials.gov/show/NCT00444951 Completed Sanofi 2008-02-29
NCT00433914 Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants https://ClinicalTrials.gov/show/NCT00433914 Completed Novartis 2007-12-31
NCT00427908 Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612 https://ClinicalTrials.gov/show/NCT00427908 Completed GlaxoSmithKline 2007-12-03
NCT00427076 Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections https://ClinicalTrials.gov/show/NCT00427076 Completed Rabin Medical Center 2014-05-31
NCT00422292 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers https://ClinicalTrials.gov/show/NCT00422292 Completed Sanofi 2009-01-31
NCT00392808 Immunogenicity of the Booster Dose of Two MenC Vaccines https://ClinicalTrials.gov/show/NCT00392808 Completed Centro Superior de Investigación en Salud Publica 2008-05-31
NCT00390143 Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612 https://ClinicalTrials.gov/show/NCT00390143 Completed GlaxoSmithKline 2009-05-31
NCT00384397 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers https://ClinicalTrials.gov/show/NCT00384397 Completed Sanofi 2008-08-31
NCT00356369 Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine https://ClinicalTrials.gov/show/NCT00356369 Completed GlaxoSmithKline 2007-09-07
NCT00355121 Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® https://ClinicalTrials.gov/show/NCT00355121 Completed Sanofi 2009-06-30
NCT00329901 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years https://ClinicalTrials.gov/show/NCT00329901 Completed Novartis 2007-05-31
NCT00329849 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age https://ClinicalTrials.gov/show/NCT00329849 Completed Novartis 2007-03-31
NCT00317109 Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevaxâ„¢ ACW at 24 to 30 m in Primed Subjects https://ClinicalTrials.gov/show/NCT00317109 Completed GlaxoSmithKline 2007-05-01
NCT00316654 Persistence of Antibody Response to N. Meningitidis Group C in Children https://ClinicalTrials.gov/show/NCT00316654 Completed Novartis 2005-10-31
NCT00311415 Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children https://ClinicalTrials.gov/show/NCT00311415 Completed Novartis 2008-04-30
NCT00310856 Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) https://ClinicalTrials.gov/show/NCT00310856 Completed Novartis 2006-11-30
NCT00310817 Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. https://ClinicalTrials.gov/show/NCT00310817 Completed Novartis 2006-05-31
NCT00310713 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine https://ClinicalTrials.gov/show/NCT00310713 Completed Novartis 2006-08-31
NCT00310700 Kinetics of B Cell Response in Infants Menjugate Vaccination https://ClinicalTrials.gov/show/NCT00310700 Completed Novartis 2005-11-30
NCT00310687 Persistence of Immune Response After Vaccination With MCC https://ClinicalTrials.gov/show/NCT00310687 Completed Novartis 2005-12-31
NCT00310674 Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age https://ClinicalTrials.gov/show/NCT00310674 Completed Novartis NA
NCT00310635 Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age https://ClinicalTrials.gov/show/NCT00310635 Completed Novartis NA
NCT00297817 Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents https://ClinicalTrials.gov/show/NCT00297817 Completed Novartis 2007-04-30
NCT00291343 Immune Response & Safety of GSK Biologicals’ Mencevaxâ„¢ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study https://ClinicalTrials.gov/show/NCT00291343 Completed GlaxoSmithKline 2007-03-15
NCT00290329 Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years https://ClinicalTrials.gov/show/NCT00290329 Completed GlaxoSmithKline 2006-10-01
NCT00271479 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine https://ClinicalTrials.gov/show/NCT00271479 Completed Epicentre NA
NCT00269477 Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® https://ClinicalTrials.gov/show/NCT00269477 Completed Sanofi 2007-02-28
NCT00262041 Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents https://ClinicalTrials.gov/show/NCT00262041 Completed Novartis 2006-03-31
NCT00262028 Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children https://ClinicalTrials.gov/show/NCT00262028 Completed Novartis 2006-11-30
NCT00262002 Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants https://ClinicalTrials.gov/show/NCT00262002 Completed Novartis 2005-07-31
NCT00258856 Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® https://ClinicalTrials.gov/show/NCT00258856 Completed Sanofi 2007-03-31
NCT00248833 Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis. https://ClinicalTrials.gov/show/NCT00248833 Completed U.S. Army Medical Research and Development Command 2006-11-30
NCT00227422 Assess the Non-inferiority of GSK Biologicals’ Mencevaxâ„¢ ACWY (Manufactured by a New Process) vs Mencevaxâ„¢ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs https://ClinicalTrials.gov/show/NCT00227422 Completed GlaxoSmithKline NA
NCT00197808 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines https://ClinicalTrials.gov/show/NCT00197808 Completed Public Health England 2010-01-31
NCT00196976 Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old https://ClinicalTrials.gov/show/NCT00196976 Completed GlaxoSmithKline 2006-03-01
NCT00196963 Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs https://ClinicalTrials.gov/show/NCT00196963 Completed GlaxoSmithKline 2005-07-31
NCT00196950 Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years https://ClinicalTrials.gov/show/NCT00196950 Completed GlaxoSmithKline 2003-10-31
NCT00161928 Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants https://ClinicalTrials.gov/show/NCT00161928 Completed Pfizer NA
NCT00145249 Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis https://ClinicalTrials.gov/show/NCT00145249 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2008-04-30
NCT00137917 Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs https://ClinicalTrials.gov/show/NCT00137917 Completed GlaxoSmithKline 2003-06-30
NCT00135564 Study to Evaluate GlaxoSmithKline (GSK) Biologicals’ MenC-TT and Hib-MenC-TT or Meningitecâ„¢ in Healthy Toddlers https://ClinicalTrials.gov/show/NCT00135564 Completed GlaxoSmithKline 2003-07-31
NCT00135486 Study to Evaluate GlaxoSmithKline (GSK) Biologicals’ MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants https://ClinicalTrials.gov/show/NCT00135486 Completed GlaxoSmithKline 2003-01-31
NCT00126984 Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine https://ClinicalTrials.gov/show/NCT00126984 Completed GlaxoSmithKline 2008-02-29
NCT00126945 Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs https://ClinicalTrials.gov/show/NCT00126945 Completed GlaxoSmithKline NA
NCT00029523 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor https://ClinicalTrials.gov/show/NCT00029523 Completed Pacira Pharmaceuticals, Inc NA
NCT00012467 Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00012467 Completed InterMune NA
NCT00002316 The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00002316 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002306 A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B https://ClinicalTrials.gov/show/NCT00002306 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002305 A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00002305 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002294 A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS https://ClinicalTrials.gov/show/NCT00002294 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002113 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. https://ClinicalTrials.gov/show/NCT00002113 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002077 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00002077 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002076 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00002076 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002075 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00002075 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002074 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome https://ClinicalTrials.gov/show/NCT00002074 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002068 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00002068 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002040 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00002040 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002019 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome https://ClinicalTrials.gov/show/NCT00002019 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002010 Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis https://ClinicalTrials.gov/show/NCT00002010 Completed NIH AIDS Clinical Trials Information Service NA
NCT00001017 Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS https://ClinicalTrials.gov/show/NCT00001017 Completed National Institute of Allergy and Infectious Diseases (NIAID) 1991-07-31
NCT00000776 Dexamethasone in Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00000776 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000708 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00000708 Completed National Institute of Allergy and Infectious Diseases (NIAID) 1991-07-31
NCT00000677 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy https://ClinicalTrials.gov/show/NCT00000677 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000639 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis https://ClinicalTrials.gov/show/NCT00000639 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03418441 Central Nervous System Infections in Denmark https://ClinicalTrials.gov/show/NCT03418441 Recruiting Aalborg University Hospital 2025-01-01
NCT03378258 Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA. https://ClinicalTrials.gov/show/NCT03378258 Completed Belfast Health and Social Care Trust 2019-06-30
NCT03252028 Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients. https://ClinicalTrials.gov/show/NCT03252028 Recruiting University Hospital, Linkoeping 2019-12-01
NCT02979951 Fosfomycin i.v. for Treatment of Severely Infected Patients https://ClinicalTrials.gov/show/NCT02979951 Recruiting Infectopharm Arzneimittel GmbH 2020-06-30
NCT02811120 PRIME Follow up - Quadri Meningo Vacinees https://ClinicalTrials.gov/show/NCT02811120 Completed Public Health England 2017-12-31
NCT02712177 Bexseroâ„¢and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization https://ClinicalTrials.gov/show/NCT02712177 Completed CHU de Quebec-Universite Laval 2010-08-31
NCT02699840 Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation https://ClinicalTrials.gov/show/NCT02699840 Completed Sanofi 2016-07-25
NCT02640677 Safety of 4CMenB Exposure During Pregnancy https://ClinicalTrials.gov/show/NCT02640677 Completed GlaxoSmithKline 2019-11-30
NCT02500511 Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study https://ClinicalTrials.gov/show/NCT02500511 Completed JN-International Medical Corporation 2015-08-31
NCT02486783 Infection, Sepsis and Meningitis in Surinamese Neonates https://ClinicalTrials.gov/show/NCT02486783 Completed Academic Hospital Paramaribo 2016-08-31
NCT02434172 CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa https://ClinicalTrials.gov/show/NCT02434172 Completed University of Zimbabwe 2017-06-30
NCT02374450 A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine https://ClinicalTrials.gov/show/NCT02374450 Active, not recruiting GlaxoSmithKline 2022-07-20
NCT02287688 Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study https://ClinicalTrials.gov/show/NCT02287688 Completed GlaxoSmithKline 2017-11-29
NCT02098525 Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT02098525 Completed Mahidol University 2013-12-31
NCT01317654 Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone https://ClinicalTrials.gov/show/NCT01317654 Completed Oxford University Clinical Research Unit, Vietnam 2008-04-30
NCT01808365 N. Meningitidis Carriage Study https://ClinicalTrials.gov/show/NCT01808365 Completed GlaxoSmithKline 2014-03-25
NCT01730690 Bacterial Meningitis in Adults: Analysis of the Determinants of Mortality and Neurosensory Sequelae https://ClinicalTrials.gov/show/NCT01730690 Completed Assistance Publique - Hôpitaux de Paris 2017-06-30
NCT01689155 Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children https://ClinicalTrials.gov/show/NCT01689155 Completed Sanofi 2015-06-30
NCT01452464 Safety of MenACWY-CRM Vaccination in Adolescents https://ClinicalTrials.gov/show/NCT01452464 Completed Novartis 2015-02-28
NCT01452438 Safety Surveillance of MenACWY-CRM Vaccine in Children https://ClinicalTrials.gov/show/NCT01452438 Completed Novartis 2015-07-31
NCT01396798 Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E. https://ClinicalTrials.gov/show/NCT01396798 Completed KU Leuven 2012-03-31
NCT01371916 Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF https://ClinicalTrials.gov/show/NCT01371916 Completed Xijing Hospital 2013-11-30
NCT04184336 Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada https://ClinicalTrials.gov/show/NCT04184336 Recruiting Canadian Paediatric Society 2020-12-31
NCT04009551 Epidemiology, Treatment and Prognosis of Neonatal Meningitis in Turkey: A Multicenter Study https://ClinicalTrials.gov/show/NCT04009551 Recruiting Zekai Tahir Burak Women’s Health Research and Education Hospital 2019-10-01
NCT03967210 Epidemiological, Clinical, Microbiological and Outcome Description of Patients With Klebsiella sp Meningitis https://ClinicalTrials.gov/show/NCT03967210 Recruiting Groupe Hospitalier Paris Saint Joseph 2021-06-01
NCT03900091 Paediatric Infections Point-Of-Care https://ClinicalTrials.gov/show/NCT03900091 Recruiting Karolinska Institutet 2020-04-30
NCT03898635 Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis https://ClinicalTrials.gov/show/NCT03898635 Recruiting Huashan Hospital 2019-05-01
NCT03856528 Infections of the Central Nervous System https://ClinicalTrials.gov/show/NCT03856528 Completed University Hospital, Basel, Switzerland 2019-09-01
NCT03798574 The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults https://ClinicalTrials.gov/show/NCT03798574 Recruiting University of Adelaide 2020-12-31
NCT03595761 Meningitis With Cerebral Vasculitis in Children https://ClinicalTrials.gov/show/NCT03595761 Completed University Hospital, Montpellier 2017-08-01
NCT01133834 Correlation Between Cytokines and the Severity of Meningococcal Disease https://ClinicalTrials.gov/show/NCT01133834 Completed University of Sao Paulo General Hospital 2011-06-30
NCT01122537 Characterization and Differential Diagnosis of Postneurosurgical Meningitis https://ClinicalTrials.gov/show/NCT01122537 Completed Asan Medical Center 2013-09-30
NCT00862277 Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine https://ClinicalTrials.gov/show/NCT00862277 Completed Sanofi 2009-03-31
NCT01657864 WEUSKOP6166: Lamotrigine and Aseptic Meningitis https://ClinicalTrials.gov/show/NCT01657864 Completed GlaxoSmithKline 2012-07-31
NCT01431326 Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care https://ClinicalTrials.gov/show/NCT01431326 Completed Duke University 2019-11-30
NCT02841254 Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies https://ClinicalTrials.gov/show/NCT02841254 Completed Nantes University Hospital 2016-05-31
NCT00728260 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds https://ClinicalTrials.gov/show/NCT00728260 Completed Sanofi 2013-05-31
NCT00450632 Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection https://ClinicalTrials.gov/show/NCT00450632 Completed University Hospital, Rouen 2011-01-31
NCT00254995 Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine https://ClinicalTrials.gov/show/NCT00254995 Completed Sanofi 2013-05-31
NCT00227214 Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar. https://ClinicalTrials.gov/show/NCT00227214 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2006-12-31
NCT00162578 Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis https://ClinicalTrials.gov/show/NCT00162578 Completed Assistance Publique - Hôpitaux de Paris NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02223637 Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry https://ClinicalTrials.gov/show/NCT02223637 Completed GlaxoSmithKline 2017-12-08
NCT03953638 Application of Next Generation Sequencing Technique in Pediatric Bacterial Meningitis https://ClinicalTrials.gov/show/NCT03953638 Recruiting Beijing Children’s Hospital 2020-01-31
NCT03499652 Neonatal Bacterial Meningitis Cohort https://ClinicalTrials.gov/show/NCT03499652 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-31